Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H23N5O5 |
Molecular Weight | 389.4057 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(N(CCCNCC(O)C3=CC(O)=CC(O)=C3)C=N2)C(=O)N(C)C1=O
InChI
InChIKey=WVLAAKXASPCBGT-UHFFFAOYSA-N
InChI=1S/C18H23N5O5/c1-21-16-15(17(27)22(2)18(21)28)23(10-20-16)5-3-4-19-9-14(26)11-6-12(24)8-13(25)7-11/h6-8,10,14,19,24-26H,3-5,9H2,1-2H3
Reproterol is a short-acting β2 adrenoreceptor agonist used in the treatment of asthma. Reproterol increases the generation of cAMP in isolated peripheral blood monocytes in vitro more effectively than does orciprenaline. In the presence of the highly potent but nonselective ß-antagonist, propranolol, the cAMP-generating action of reproterol was inhibited only partially. Reproterol has gained wide use when it was licensed as a fixed combination therapy with cromoglycate. Until today, the bronchodilator effects of reproterol and the bronchoprotective and anti-inflammatory actions of cromoglycate combined in one inhaler remain the successful fixed combination of a disease-modifying and symptomatic drug for the treatment of asthma.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Phosphodiesterase, mouse Sources: https://www.ncbi.nlm.nih.gov/pubmed/15219266 |
52.0 µM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of reproterol either alone or combined with disodium cromoglycate on airway responsiveness to methacholine. | 2005 |
|
Mononuclear cell membranes: stabilization by reproterol and cromoglycate, destabilization by fenoterol and salbutamol. | 2006 |
|
Multiresidue analysis of beta-agonists in bovine and porcine urine, feed and hair using liquid chromatography electrospray ionisation tandem mass spectrometry. | 2008 May |
|
Exercise-induced asthma: critical analysis of the protective role of montelukast. | 2009 Oct 22 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R03CC14
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
WHO-VATC |
QR03CC14
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
WHO-ATC |
R03AC15
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
WHO-VATC |
QR03AK05
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
WHO-ATC |
R03AK05
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
||
|
WHO-VATC |
QR03AC15
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB10283MIG
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
REPROTEROL
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
25654
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
DB12846
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
C014792
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
258-956-1
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
C152194
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
11941YC6RN
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
m9529
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL1095607
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
35373
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | RxNorm | ||
|
54063-54-6
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
100000080550
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
DTXSID8023553
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
2368
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY | |||
|
3501
Created by
admin on Mon Mar 31 19:21:41 GMT 2025 , Edited by admin on Mon Mar 31 19:21:41 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)